ABBVie today announced that the New England Journal of Medicine has published 12-week results from the Phase 3 ADVANCE trial evaluating atogepant for the preventive treatment of migraine in adults who meet criteria for episodic migraine. The study, which enrolled adult participants experiencing 4 to 14 migraine days per month, found that all active treatment arms of atogepant 10 mg, 30 mg, and 60 mg once-daily .
Practitioners will want to remain current on the evolving law of petitioner estoppel. As with many provisions of the America Invents Act, the contours of the issue are still developing through case law.
Delaware Court Applies mondaq.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mondaq.com Daily Mail and Mail on Sunday newspapers.